Journal Mobile Options
Table of Contents
Vol. 116, No. 3, 2006
Issue release date: October 2006

Bortezomib-Induced Rhabdomyolysis in Multiple Myeloma

Cibeira M.T. · Mercadal S. · Arenillas L. · Muntañola A. · Salamero O. · Bladé J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Although multiple myeloma (MM) remains an incurable disease, its treatment has improved over the past decade. This improvement has been at least in part due to the introduction of novel antimyeloma agents with new mechanisms of action, including those that target both myeloma cells and the tumor microenvironment, with antiangiogenic and immunomodulatory properties. Among these drugs, bortezomib (Velcade®), a selective proteasome inhibitor, has been approved for the treatment of relapsed and refractory MM patients after one line of therapy. The toxicity profile of bortezomib includes gastrointestinal symptoms, fatigue, thrombocytopenia, peripheral neuropathy, postural hypotension, as well as some uncommon events. A patient with relapsed MM who developed recurrent bortezomib-induced rhabdomyolysis is reported. To our knowledge, this adverse event has not been previously described is this context.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bladé J, Vesole DH, Gertz MA: Transplantation for multiple myeloma: who, when, how often? Blood 2003;102:3469–3477.
  2. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Clin Cancer Res 2001;61:3071–3076.
  3. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
  4. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski R, Kuter D, Hideshima T, Esseltine DL, Anderson KC: Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory multiple myeloma: an update with additional follow-up. Hematol J 2004;5(suppl 2):S103–S104.
  5. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165–172.
  6. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer E, Facon T, Harousseau J, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel J, Blade J, Boccadoro M, Cavenagh J, Dalton W, Boral A, Schenkein D, Anderson K: Bortezomib demonstrates superior efficacy to high-dose dexamethasone in relapsed multiple myeloma: final report of the APEX study. http://www.abstracts2view.com/hem_sandiego2004/2004;104:abstract 336.5.
  7. Jagannath S, Durie B, Wolf JL, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Crowley J, Schenkein D: A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma. Blood 2004;104:98a–99a.
  8. Berenson JR, Jagannath S, Barlogie B, Siegel D, Alexanian R, Irwin D, Srkalovic G, Richardson PG, Esseltine DL, Anderson KC: The safety of prolonged therapy with the proteasome inhibitor bortezomib (Velcade) in relapsed and/or refractory multiple myeloma (MM). Hematol J 2004;5(suppl 2):S129.
  9. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
  10. Richardson P, Briemberg H, Jagannath S, Barlogie B, Berenson J, Singhal S, Traynor A, Siegel D, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski R, Kuter D, Esseltine D, Adams J, Schenkein DP, Wen P, Amato A, Anderson KC: Peripheral neuropathy following bortezomib (Velcade, formerly PS-341) therapy in patients with advanced multiple myeloma (MM): characterization and reversibility. Blood 2003;102:149a.
  11. Terpos E, Politou M, Rahemtulla A: Tumour lysis syndrome in multiple myeloma after bortezomib (Velcade) administration. J Cancer Res Clin Oncol 2004;130:623–625.
  12. Mehta J, Jakob C, Singhal S, Stadtmauer E, Richardson P, Vesole D, Boral AL, Esseltine DL, Sezer O: Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma. Blood 2003;102:386b.
  13. Rosiñol L, Montoto S, Cibeira MT, Bladé J: Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Arch Intern Med 2005;165:464–465.
  14. Warren JD, Blumbergs PG, Thompson PD: Rhabdomyolysis: a review. Muscle Nerve 2002;25:332–347.
  15. Allison RC, Bedsole DL: The other medical causes of rhabdomyolysis. Am J Med Sci 2003;326:79–88.
  16. Sauret JM, Marinides G, Wang GK: Rhabdomyolysis. Am Fam Physician 2002;65:907–912.
  17. Visweswaran P, Guntupalli LJ: Rhabdomyolysis. Crit Care Clin 1999;15:415–428.
  18. Ward MM: Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988;148:1553–1557.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00